PI3K-AKT pathway polymerase chain reaction (PCR) array analysis of epilepsy induced by type II focal cortical dysplasia

Genetics and Molecular Research

Volumn 14, Issue 3, 2015, Pages 9994-10000

  Lin, Y X ^a   Lin, K ^b   Liu, X X ^a   Kang, D Z ^a   Ye, Z X ^a   Wang, X F ^a   Zheng, S F ^a   Yu, L H ^a   Lin, Z Y ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN PROVINCIAL HOSPITAL   (China)

Author keywords

Cortical dysplasia; Epilepsy; Gene chip; PI3K AKT signaling pathway

Indexed keywords

BETA1 INTEGRIN; BRUTON TYROSINE KINASE; CD14 ANTIGEN; FAS LIGAND; HEAT SHOCK PROTEIN 27; INITIATION FACTOR 4E; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; PROTEIN KINASE B; S6 KINASE;

ARTICLE; BRAIN DAMAGE; BTK GENE; CASE REPORT; CD14 GENE; CELL ADHESION; CELL MIGRATION; CELL SIZE; CONTROLLED STUDY; CORTICAL DYSPLASIA; EIF4BPI GENE; EPILEPSY; EPILEPTOGENESIS; FASLG GENE; FBJ GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; HISTOPATHOLOGY; HSPB1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; ITGB1 GENE; JUN GENE; MYD88 GENE; PAK1 GENE; PIK3CG GENE; POLYMERASE CHAIN REACTION SYSTEM; PRS6KA1 GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TCL1A GENE; GENETICS; MALFORMATION OF CORTICAL DEVELOPMENT GROUP I; METABOLISM; SIGNAL TRANSDUCTION;

EPILEPSY; GENE EXPRESSION; HUMANS; MALFORMATIONS OF CORTICAL DEVELOPMENT, GROUP I; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84940199072     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.August.21.5     Document Type: Article

References (23)

1. Blümcke I, Thom M, Aronica E, Armstrong DD, et al. (2011). The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 52: 158-174.
2. Cardamone M, Flanagan D, Mowat D, Kennedy SE, et al. (2014). Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J. Pediatr. 64: 1195-1200.
3. Chen J, Tsai V, Parker WE, Aronica E, et al. (2012). Detection of human papillomavirus in human focal cortical dysplasia type IIB. Ann. Neurol. 72: 881-892.
4. Crino PB (2007). Focal brain malformations: a spectrum of disorders along the mTOR cascade. Novartis Found. Symp. 288: 260-272; Discussion 272-281.
5. Friedman WJ (2010). Proneurotrophins, seizures, and neuronal apoptosis. Neuroscientist 16: 244-252.
6. Iyer A, Zurolo E, Spliet WG, van Rijen PC, et al. (2010). Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. Epilepsia 51: 1763-1773.
7. Iyer A, Prabowo A, Anink J, Spliet WG, et al. (2014). Cell injury and premature neurodegeneration in focal malformations of cortical development. Brain Pathol. 24: 1-17.
8. Lee JY, Park AK, Lee ES, Park WY, et al. (2014). miRNA expression analysis in cortical dysplasia: Regulation of mTOR and LIS1 pathway. Epilepsy Res. 108: 433-441.
9. Lim KC and Crino PB (2013). Focal malformations of cortical development: New vistas for molecular pathogenesis. Neuroscience 252: 262-276.
10. Ljungberg MC, Bhattacharjee MB, Lu Y, Armstrong DL, et al. (2006). Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann. Neurol. 60: 420-429.
11. Lu Z, Hu X, Li Y, Zheng L, et al. (2004). Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J. Biol. Chem. 279: 35664-35670.
12. Magri L, Cominelli M, Cambiaghi M, Cursi M, et al. (2013). Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models. Dis. Model Mech. 6: 1185-1197.
13. Meng XF, Yu JT, Song JH, Chi S, et al. (2013). Role of the mTOR signaling pathway in epilepsy. J. Neurol. Sci. 332: 4-15.
14. Miyata H, Chiang AC and Vinters HV (2004). Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis. Ann. Neurol. 56: 510-519.
15. Orlova KA, Parker WE, Heuer GG, Tsai V, et al. (2010a). STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J. Clin. Invest. 120: 1591-1602.
16. Orlova KA, Tsai V, Baybis M, Heuer GG, et al. (2010b). Early progenitor cell marker expression distinguishes type II from type I focal cortical dysplasias. J. Neuropathol. Exp. Neurol. 69: 850-863.
17. Parker WE, Orlova KA, Parker WH, Birnbaum JF, et al. (2013). Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci. Transl. Med. 5: 182ra153.
18. Scheffer IE, Heron SE, Regan BM, Mandelstam S, et al. (2014). Mutations in mTOR regulator DEPDC5 cause focal epilepsy with brain malformations. Ann. Neurol. 75: 782-787.
19. Schick V, Majores M, Engels G, Spitoni S, et al. (2006). Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias. Acta Neuropathol. 112: 715-725.
20. Schick V, Majores M, Engels G, Hartmann W, et al. (2007). Differential Pi3K-pathway activation in cortical tubers and focal cortical dysplasias with balloon cells. Brain Pathol. 17: 165-173.
21. Weichhart T and Säemann MD (2009). The multiple facets of mTOR in immunity. Trends Immunol. 30: 218-226.
22. Wong M (2013). Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations. Exp. Neurol. 244: 22-26.
23. Yasin SA, Ali AM, Tata M, Picker SR, et al. (2013). mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis. Acta Neuropathol. 126: 207-218.